- Home
- AVY vs RPRX Comparison
AVY vs RPRX Comparison
Compare AVY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVY
- RPRX
- Stock Information
- Founded
- AVY 1935
- RPRX 1996
- Country
- AVY United States
- RPRX United States
- Employees
- AVY N/A
- RPRX N/A
- Industry
- AVY Containers/Packaging
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- AVY Consumer Discretionary
- RPRX Health Care
- Exchange
- AVY Nasdaq
- RPRX Nasdaq
- Market Cap
- AVY 13.4B
- RPRX 14.2B
- IPO Year
- AVY N/A
- RPRX 2020
- Fundamental
- Price
- AVY $172.16
- RPRX $33.15
- Analyst Decision
- AVY Buy
- RPRX Strong Buy
- Analyst Count
- AVY 11
- RPRX 4
- Target Price
- AVY $206.05
- RPRX $42.50
- AVG Volume (30 Days)
- AVY 812.4K
- RPRX 3.7M
- Earning Date
- AVY 04-23-2025
- RPRX 05-08-2025
- Dividend Yield
- AVY 2.18%
- RPRX 2.65%
- EPS Growth
- AVY 27.06
- RPRX 37.42
- EPS
- AVY 8.69
- RPRX 2.45
- Revenue
- AVY $8,752,700,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- AVY $2.68
- RPRX $31.30
- Revenue Next Year
- AVY $4.17
- RPRX $5.82
- P/E Ratio
- AVY $19.86
- RPRX $13.54
- Revenue Growth
- AVY 3.58
- RPRX 1.12
- 52 Week Low
- AVY $157.00
- RPRX $24.05
- 52 Week High
- AVY $233.48
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- AVY 49.92
- RPRX 57.43
- Support Level
- AVY $168.64
- RPRX $31.97
- Resistance Level
- AVY $174.84
- RPRX $34.11
- Average True Range (ATR)
- AVY 3.79
- RPRX 0.71
- MACD
- AVY 0.53
- RPRX 0.09
- Stochastic Oscillator
- AVY 47.55
- RPRX 62.06
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.